About this item:

16 Views | 5 Downloads

Author Notes:

Javed Butler, MD MPH, Emory Clinical Cardiovascular Research Institute, 1462 Clifton Road NE, Suite AT 504, Atlanta, GA 30322. Telephone No: 404-778-5136 Fax No: 404-778-5285 javed.butler@emory.edu.

We want to thank Ms. Fumiko Inoue for organizing this meeting.

Subjects:

Keywords:

  • Science & Technology
  • Life Sciences & Biomedicine
  • Cardiac & Cardiovascular Systems
  • Cardiovascular System & Cardiology
  • epidemiology
  • heart failure
  • preserved ejection fraction
  • prognosis
  • treatment
  • RANDOMIZED CONTROLLED-TRIAL
  • QUALITY-OF-LIFE
  • VENTRICULAR DIASTOLIC DYSFUNCTION
  • CONVERTING ENZYME-INHIBITORS
  • PRIOR MYOCARDIAL-INFARCTION
  • NATRIURETIC PEPTIDE LEVELS
  • SINGLE-BLIND TRIAL
  • EXERCISE CAPACITY
  • SYSTOLIC FUNCTION
  • ELDERLY-PATIENTS

Developing Therapies for Heart Failure With Preserved Ejection Fraction Current State and Future Directions

Show all authors Show less authors

Tools:

Journal Title:

JACC: Heart Failure

Volume:

Volume 2, Number 2

Publisher:

, Pages 97-112

Type of Work:

Article | Post-print: After Peer Review

Abstract:

The burden of heart failure with preserved ejection fraction (HFpEF) is considerable and is projected to worsen. To date, there are no approved therapies available for reducing mortality or hospitalizations for these patients. The pathophysiology of HFpEF is complex and includes alterations in cardiac structure and function, systemic and pulmonary vascular abnormalities, end-organ involvement, and comorbidities. There remain major gaps in our understanding of HFpEF pathophysiology. To facilitate a discussion of how to proceed effectively in future with development of therapies for HFpEF, a meeting was facilitated by the Food and Drug Administration and included representatives from academia, industry, and regulatory agencies. This document summarizes the proceedings from this meeting.

Copyright information:

© 2014 American College of Cardiology Foundation.

This is an Open Access work distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (http://creativecommons.org/licenses/by-nc-nd/4.0/).

Creative Commons License

Export to EndNote